

## Translating Expression Profiling into a Clinically Feasible Test to Predict Neuroblastoma Outcome

Alexander Schramm, Jo Vandesompele, Johannes H. Schulte, Sabine Dreesmann, Lars Kaderali, Benedikt Brors, Roland Eils, Frank Speleman, and Angelika Eggert

**Abstract Purpose:** To assess the feasibility of predicting neuroblastoma outcome using highly parallel quantitative real-time PCR data.

**Experimental Design:** We generated expression profiles of 63 neuroblastoma patients, 47 of which were analyzed by both Affymetrix U95A microarrays and highly parallel real-time PCR on microfluidic cards (MFC; Applied Biosystems). Top-ranked genes discriminating patients with event-free survival or relapse according to high-level analysis of Affymetrix chip data, as well as known neuroblastoma marker genes (*MYCN* and *NTRK1/TrkA*), were quantified simultaneously by real-time PCR. Analysis of PCR data was accomplished using high-level bioinformatics methods including prediction analysis of microarray, significance analysis of microarray, and Computerized Affected Sibling Pair Analyzer and Reporter.

**Results:** Internal validation of the MFC method proved it highly reproducible. Correlation of MFC and chip expression data varied markedly for some genes. Outcome prediction using prediction analysis of microarray on real-time PCR data resulted in 80% accuracy, which is comparable to results obtained using the Affymetrix platform. Real-time PCR data were useful for risk assessment of relapsing neuroblastoma ( $P = 0.0006$ , log-rank test) when Computerized Affected Sibling Pair Analyzer and Reporter analysis was applied.

**Conclusions:** These data suggest that multiplex real-time PCR might be a promising approach to reduce the complexity of information obtained from whole-genome array experiments. It could provide a more convenient and less expensive tool for routine application in a clinical setting.

Neuroblastoma is a common childhood tumor derived from the sympathetic nervous system. To avoid overtreatment of spontaneously regressing tumors and undertreatment in aggressive neuroblastomas, precise prediction of tumor behavior and risk assessment of each individual patient at diagnosis is a major goal of current neuroblastoma research. Similar to analyses in other cancer entities, several genome-wide mRNA expression profiling studies have identified reliable outcome predictors for neuroblastoma, but with little or no overlap in the decision-making genes (1–3). The comparability of microarray data remains a major concern in the interpretation of expression analyses. Today, numerous options are available to carry out whole-genome surveys of gene expression owing to a variety of technical platforms and a still increasing number of

distributors. A comprehensive study of six microarray technologies recently addressed the overall consistency within each platform, as well as the correlation among replicates within and between technologies (4). The authors concluded that technological differences may influence the results of transcriptional profiling given high-quality arrays and the appropriate normalization, but that the primary factor determining variance is biological rather than technological. This is reassuring for the clinical usefulness of microarray data because bridging the gap between bench-top microarray analysis and clinical diagnostics is one of the major goals not only in current cancer research but also in molecular medicine in general. However, translation of expression profiling results into routine clinical diagnostics requires a less complex alternative technology for reliable outcome prediction. An essential first step is the implementation of standard operating procedures for target preparation, the hybridization process, and readout formats, as well as between-laboratory comparisons of microarray results (5, 6). The validation of results on technically independent platforms is one of the prerequisites for the transfer of results from molecular biology into a clinical setting (7). The validation by real-time PCR, which is currently the gold standard for measuring gene expression, is considered to be the final proof of array data. A successful approach to evaluate the results from different array systems by means of real-time PCR has previously been published (8). The authors compared data from several expression studies to build a model consisting of only six genes, the expression of which predicted the outcome

**Authors' Affiliation:** Division of Hematology and Oncology, University Children's Hospital Essen, Essen, Germany

Received 8/14/06; revised 10/31/06; accepted 11/15/06.

**Grant support:** The German National Genome Network (BMBF/NGNF2), AE and RE.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

**Requests for reprints:** Angelika Eggert, Division of Hematology and Oncology, University Children's Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany. Phone: 49-201-723-3755; Fax: 49-201-723-5750; E-mail: angelika.eggert@uni-essen.de.

© 2007 American Association for Cancer Research.  
doi:10.1158/1078-0432.CCR-06-2032

of diffuse large B-cell lymphoma. Subsequently, it was pointed out that these data must also be evaluated carefully and that validity should be assessed using time-dependent receiver operating characteristic curves instead of risk group stratification (9). Because most gene classifiers identified to date as reliable outcome predictors for different cancer entities including neuroblastoma consist of >20 genes (1, 3, 10), validation of every gene by conventional real-time PCR is not suited to the clinical setting. Technologies appropriate for clinical applications must not only fulfill the requirement of high reproducibility but must also be convenient and efficient in their handling. With the introduction of TaqMan Low Density Arrays (Applied Biosystems, Foster City, CA), researchers can simultaneously assay the RNA expression levels of up to 384 genes on a single microfluidic card (MFC). In principle, this technology allows the rapid validation of differentially expressed genes in a genome-wide microarray study. To assess the potential of these MFCs as an alternative application for candidate gene analysis and diagnostics in a routine clinical setting, we here analyzed a clinically well-defined cohort of 63 primary neuroblastomas. Genes predictive for recurrence of disease according to a recently published microarray study (1), as well as established biological factors including *MYCN* and *NTRK1/TrkA*, were selected for the construction of a MFC (Table 1). Interassay reproducibility of data obtained from eight MFCs representing the 63 patients was subsequently evaluated by measuring one sample from each of these cards on a 9th card ("reference card"). Normalized real-time PCR values were also compared with expression data from Affymetrix oligonucleotide arrays from a subgroup of the same patients. Finally, the usefulness of MFC-derived results for outcome prediction and individual risk assessment of neuroblastoma patients was evaluated.

**Table 1.** Clinical characteristics of neuroblastoma patients in this study

	<i>n</i> (%)
Age (y)	
<1	30 (47.6)
>1	33 (52.4)
International Neuroblastoma Staging System stage	
I	21 (33.3)
II	13 (20.6)
III	7 (11.1)
IV	14 (22.2)
IVs	8 (12.7)
MYCN status	
Normal	59 (93.5)
Amplified (>10 copies)	4 (6.5)
Status of chromosome 1p	
No LOH 1p	46 (73.0)
LOH 1p	15 (23.8)
Undetermined	2 (3.2)

NOTE: International Neuroblastoma Staging System staging was done by local pathologists and confirmed independently. MYCN amplification and 1p loss of heterozygosity were determined in the course of routine diagnostics by Southern blotting and fluorescence *in situ* hybridization, respectively.  
Abbreviation: LOH, loss of heterozygosity.

**Table 2.** List of genes included on the MFC and used for parallel real-time PCR analyses

Gene	Assay no.	Function	Affx-ID
<i>MYCN</i>	Hs00232074_m1	GOI	2078_s_at
<i>COX6C</i>	Hs00269977_m1	GOI	36165_at
<i>LGALS1</i>	Hs00169327_m1	GOI	33412_at
<i>PTPRF</i>	Hs00160858_m1	GOI	36204_at
<i>TKT</i>	Hs00169074_m1	GOI	38789_at
<i>LDHA</i>	Hs00855332_g1	GOI	41485_at
<i>PFN2</i>	Hs00160050_m1	GOI	38840_s_at
<i>PSMD10</i>	Hs00829508_s1	GOI	37350_at
<i>NEDD8</i>	Hs00362398_m1	GOI	1695_at
<i>NTRK1</i>	Hs00176787_m1	GOI	32754_at
<i>TCEB1</i>	Hs00255010_m1	GOI	1399_at
<i>CDC42</i>	Hs00741586_mH	GOI	39736_at
<i>AHSA1</i>	Hs00201602_m1	GOI	40979_at
<i>NME2</i>	Hs00267363_m1	GOI	1980_s_at
<i>PSMB5</i>	Hs00605652_m1	GOI	37666_at
<i>DDX21</i>	Hs00190952_m1	GOI	40490_at
<i>CHD5</i>	Hs00395930_m1	GOI	32093_at
<i>NDUFAB1</i>	Hs00192290_m1	GOI	35297_at
<i>HSPCB</i>	Hs00607336_gH	GOI	33984_at
<i>GA17</i>	Hs00272235_m1	GOI	35814_at
<i>HPRT1</i>	Hs99999909_m1	CONTROL	
<i>GAPDH</i>	4342376	CONTROL	
<i>UBC</i>	Hs00824723_m1	CONTROL	
<i>SDHB</i>	Hs00268117_m1	CONTROL	

NOTE: Assay no. depicts the internal ABI description for the real-time assay. Function depicts whether the gene serves as a CONTROL or is a gene of interest (GOI). Affx-ID defines the probe set used for gene selection on the Affymetrix U95A chip.

## Materials and Methods

**Patient cohort and RNA preparation from primary neuroblastomas.** RNA preparation from neuroblastomas was done as previously described (1). Data collection, microarray data analysis, and the majority of the patient cohort have been documented before (1). Briefly, expression profiles from 68 neuroblastoma patients had been obtained using Affymetrix U95A chips. Expression patterns characteristic for biological and clinical features were obtained. Of these 68 samples, 47 were included in the present study, solely chosen on the basis of availability of RNA from the same tumor sample. For independent validation of the data, 16 additional patients with neuroblastoma were included. Written informed consent was obtained from patients or their parents. To avoid biasing the methods towards event-free survival, no patient was included in the study showing event-free survival, *MYCN* amplification or loss of 1p, and <2 years of follow-up. Mean and median follow-up were 1,443 and 1,401 days, respectively. Patient characteristics are listed in Table 2.

**Construction of a neuroblastoma-specific MFC.** A set of 39 genes obtained by prediction analysis of microarray (PAM) data was shown to be able to discriminate between neuroblastoma patients with recurrent tumors and those with no evidence of disease following initial therapy (1). For the setup of the MFC, we used the top-ranked genes of the PAM classifier and we also included known factors contributing to neuroblastoma biology (*MYCN* and *NTRK1/TrkA*), as well as four reference genes (*GAPDH*, *HPRT1*, *SDHA*, and *UBC*), as previously suggested (11). Genes and the corresponding assays on demand used for the setup of the MFC are listed in Table 1.

**Statistical analysis of real-time PCR data.** Real-time PCR data were preprocessed and stored in SDS 2.2 software (Applied Biosystems). Results from each run were analyzed separately using a software-defined baseline and a manual threshold between 0.1 and 0.5 to record the cycle

thresholds ( $C_t$ ). Data normalization was done with the geometric mean of four reference genes using qBase (Hellemans et al.)<sup>1</sup> and normalized data were subsequently imported into R<sup>2</sup> using the stats package.


**High-level informatics for comparison of real-time PCR and Affymetrix microarray data.** Statistical calculations were done using R.<sup>2</sup> The R implementation of significance analysis of microarray (SAM; ref. 12) was used with default parameters, for the two-class unpaired case, with  $t$  statistic. Support Vector Machine (SVM) calculations were carried out using the LIBSVM library (13), with the interface provided by R. A sigmoidal kernel was used, with parameters  $\gamma = 0.5$ ,  $\cos t = 1$ ,  $\varepsilon = 0.1$ . The PAM (14) implementation in R was used with default values except for the threshold, which was set to zero. Decision trees were constructed using the implementation of recursive partitioning and regression trees in R. Standard parameters were used for the classification tree, with the *minsplit* parameter set to 5. Computerized Affected Sibling Pair Analyzer and Reporter (CASPAR; ref. 15) was used to predict survival times for the individual patient. In addition, an adaptation of CASPAR for classification problems was used to distinguish relapsed from cured patients. In essence, this adaptation uses a logistic regression model for class assignments instead of the Cox model used by standard CASPAR for survival analysis.

## Results

**Assessment of mRNA expression using MFCs is reproducible.** To evaluate the potential of MFCs as a useful alternative application for candidate gene analysis and prognosis prediction in a routine clinical setting, we constructed a neuroblastoma-specific MFC and reanalyzed neuroblastoma samples previously studied by Affymetrix U95A microarrays. Genes were selected for the setup of the neuroblastoma-specific MFC based on the PAM analysis discriminating between neuroblastoma patients with or without relapse of disease (1). We also added known biological factors including the *MYCN* oncogene and the neurotrophin receptor *TrkA/NTRK1*, as well as genes from chromosome 1p, a region frequently deleted in neuroblastoma. Additionally, four reference genes were also included on the MFC (for a list of genes and assays, see Table 1). Because multiplex real-time PCR may yield varying results due to methodologic difficulties including inconsistent amplification efficiency, we assessed reproducibility of the MFCs as a first step of quality control by evaluating one neuroblastoma sample from each card on an independent card (reference card). A total of 63 neuroblastomas were analyzed using eight cards, and one sample from each of these cards was randomly chosen for analyses on the reference card. In summary, the mean  $\delta C_t$  between the two independent runs for the same sample was 0.4, which is equivalent to a 1.3-fold difference or 32.2% difference assuming 100% amplification efficiency. The median difference was 0.29- or 1.22-fold (i.e., half of the sample gene pairs were within 21.9% difference). Analysis of the complete cumulative difference distribution indicated that 75% of the sample gene pairs were within 1.47-fold, 90% within 1.82-fold, and 95% within 2.15-fold (Fig. 1A). MFC reproducibility between independent runs seemed to be somewhat dependent on the target gene, in particular for low-abundance transcripts. For instance, we observed consistently higher  $\delta C_t$  values for the *NME2* gene, which is

expressed at low levels. On the whole, our data indicate a high level of intercard reproducibility.


**Expression analysis of neuroblastoma-specific genes by MFCs and Affymetrix U95A microarrays.** The MFC quantitative PCR results were compared with those obtained by Affymetrix U95A chips because there was considerable overlap of genes included on the MFC and the previously described Affymetrix-based PAM classifier discriminating patients with event-free survival or early relapse. Following normalization of the real-time PCR data, Pearson correlation coefficients between array and PCR were calculated for each gene. Correlation coefficients ranged from 0 (no correlation; *COX6C*) to 0.95 (high correlation; *MYCN*), indicating that the Affymetrix array and MFC quantitative PCR platform produced different results for the expression of some genes of interest (Fig. 1B). Univariate analysis of the individual genes was done to assess their ability to distinguish between patients with or without relapse. Application of  $t$  statistics to the results from the MFCs revealed that expression of two genes, *NEDD8* and *PSMD10*, differed significantly between event-free survival and relapse patients, confirming our previous results from Affymetrix arrays (1). All but one of the remaining genes displayed the same direction of regulation, as was predicted by PAM analysis of the Affymetrix array results, but did not reach statistical significance. SAM analysis of MFC quantitative PCR data indicated that high *CDC42*, *PTPRF*, and *NTRK1* expression was associated with event-free survival, whereas high *LDHA* and *PSMD10* expression correlated with relapse of disease (Fig. 2A).



**Fig. 1.** A, cumulative  $\delta C_t$  distribution of independent runs of real-time PCR using the MFC described. The graph indicates high reproducibility of the PCR reaction because the median difference (dotted lines) was 0.4, which is equivalent to a 1.3-fold difference between two measurements of the same sample and the same primer on two cards. B, correlation between Affymetrix array and real-time PCR data given as Pearson correlation coefficients. Data were obtained for 47 tumors analyzed on both platforms. The gene descriptions are those given in Table 1.

<sup>1</sup> <http://medgen.ugent.be/qbase>

<sup>2</sup> <http://www.r-project.org>



**Fig. 2.** A, SAM plot obtained for outcome prediction of neuroblastoma patients based on real-time PCR data. The figure shows the observed versus the expected score, indicating that CDC42, PTPRF, and NTRK1 are elevated in patients with event-free survival, whereas patients with relapse show significant ( $q$  value  $<1\%$ ) up-regulation of PSMD10 and LDHA (gray circles). B, SAM plot obtained for prediction of chromosome 1p status of neuroblastoma patients based on real-time PCR data. Observed versus expected scores, indicating that PSMD10 and MYCN are elevated in patients with 1p loss of heterozygosity, whereas patients with normal 1p status significantly ( $q$ -value  $<1\%$ ) show up-regulation of NTRK1, PTPRF, and CDC42 (gray circles).

**Prediction of clinical parameters and patient outcome by supervised analysis of real-time PCR results.** We next assessed the correct assignment of the 63 patients (including 47 patient samples from our previously published microarray study) to their clinically defined groups using MFC quantitative PCR data. In the aforementioned analysis of primary neuroblastomas on the Affymetrix platform, a considerable percentage of samples failed to pass the inclusion quality criteria for the microarray study. Nevertheless, 16 of these samples had a RNA quality sufficient for real-time PCR analysis as judged by  $A_{260}/A_{280}$  ratios and conventional PCR using reference genes (data not shown). These samples were included for MFC analysis as a test set, mimicking the clinical situation in which not every tumor sample is qualitatively suitable for microarray analysis. Training of the class prediction models was done using the MFC quantitative PCR data from the 47 patients already profiled using Affymetrix microarrays. Event-free survival of neuroblastoma patients was predicted with 75% classification accuracy (12 of 16) in the validation set using SVM and 81% classification accuracy (13 of 16) using PAM. Interestingly, PAM correctly predicted all relapses in this independent data set. CASPAR analysis and decision trees resulted in 69% classification accuracy (11 of 16). All analysis methods applied here misclassified the same three patients. Interestingly, predictions

of all methods used PTPRF expression and one of the proteasome components (*PSMB5*, *NEDD8*, or *PSMD10*) and all but one method include *NTRK1*, *CDC42*, and *LDHA* as top-ranked genes (Table 3), which is also supported by SAM analysis (Fig. 2A). Because we included genes located on chromosome 1p on the MFC, we also tested whether it was possible to predict the 1p status of neuroblastoma patients using SAM and PAM analyses of MFC quantitative PCR data. Interestingly, we not only found a high correlation between 1p loss and expression of genes in the MYCN amplicon, which is a well-known phenomenon, but also a strong association of 1p loss and expression of proteasomal components (*PSMD10* and, to a lesser extent, *PSMB5* and *NEDD8*; Fig. 2B) using SAM analysis. The expression of *NTRK1* and 1p genes was anticorrelated with 1p loss. PAM-based prediction of 1p status using a leave-one-out approach resulted in 88% prediction accuracy (Table 4). Taken together, these results show a high accuracy of MFC-based predictions for clinical features of neuroblastoma.

**Individual risk prediction of relapsing neuroblastoma using PAM and CASPAR.** To assess the individual risk of neuroblastoma patients for suffering a relapse, PAM was applied to the entire data set using leave-one-out cross-validation. This analysis method trains the classifier on all but one patient (i.e.,  $n = 62$ ), then uses this optimized classifier to predict the outcome of the remaining patient. The prediction accuracy of the PAM classifier was close to 80% (79.4%). Transforming these results for PAM predictions “relapse/no relapse” into a survival time analysis revealed that the class prediction was highly effective and significant ( $P < 0.0001$ ; Fig. 3).

CASPAR was applied to the MFC quantitative PCR data to calculate cure or time to relapse for each patient individually using leave-one-out cross-validation. The graphical representation of the receiver operating characteristics as a measure of sensitivity and specificity of CASPAR predictions is summarized in Fig. 4A [area under the curve (AUC) plot]. An AUC value of 1 implies perfect prediction in terms of sensitivity and specificity. AUC values of  $\sim 0.7$  for time points  $>3$  years were obtained based on the predictions by CASPAR using the data presented here.

**Table 3.** Genes involved in the decision process for discriminating neuroblastoma patients with either event-free survival or relapse

	No. methods using this gene
Genes associated with event-free survival	
<i>PTPRF</i>	4
<i>NTRK1</i>	3
<i>CDC42</i>	3
<i>NME2</i>	1
Genes associated with relapse	
<i>LDHA</i>	3
<i>PSMD10</i>	3
<i>NEDD8</i>	2
<i>AHSA1</i>	1
<i>PSMB5</i>	1

NOTE: Because SAM, PAM, CASPAR, and decision trees were used for prediction analyses, number of methods using this gene sums up how many methods selected it for decision making.



**Table 4.** Prediction of 1p status using PAM analysis with leave-one-out cross-validation of MFC qPCR data

TRUEGROUP	PREDSGROUP	
	Deletion	No deletion
Deletion	5	2
No deletion	4	39

NOTE: Prediction accuracy was 88%, with 71% sensitivity and 90% specificity.


This is comparable to the predictive power of other recently published microarray studies (15–18). As most of the neuroblastoma relapses occur within the first 3 years after diagnosis, we analyzed the power of CASPAR predictions for this time frame. For this purpose, patients were divided into two groups based on the predictions from CASPAR analysis: those patients with a predicted time to relapse of <3 years or those with predicted event-free survival or time to relapse of >3 years. The resulting Kaplan-Meier plot shows a highly significant separation of patients with event-free survival or relapse (Fig. 4B), which was confirmed by log-rank test ( $P = 0.0006$ ). Thus, CASPAR-based analysis of MFC quantitative PCR data is a useful tool for predicting the individual patient risk of neuroblastoma relapse.

## Discussion


A major drawback for the clinical relevance of microarray analysis is the difficulty to compare results obtained on different platforms. Strategies to render these platforms compatible are urgently needed, and some approaches have already been described (4, 19–21). To date, attempts at prediction of outcome in neuroblastoma have relied on single expression profiling platforms, partly without addressing the need for independent validation procedures with features qualifying them for convenient use at the bedside (2, 3). As an independent technology for validation of microarray data derived from different platforms, quantitative real-time PCR has turned out to be the method of choice to obtain reliable information about gene expression. Approaches based on quantitative real-time PCR have also been used for neuroblastoma biomarker discovery, sometimes in large cohorts (22–26). All of these studies used single-tube assays lacking efficient handling procedures. However, technologies appropriate for clinical applications not only have to fulfill the requirement of high reproducibility and accuracy but must also be feasible and efficient in the clinical setting. In contrast to conventional real-time PCR analysis, this demand is met by the introduction of MFCs or TaqMan Low Density Arrays (Applied Biosystems). We therefore aimed to assess the value of MFCs as a useful tool for the clinical application of outcome predictors that were previously identified using microarray analyses. Thus, we compared the clinical significance of previously obtained results from a neuroblastoma microarray study to the significance of results obtained on the same primary tumor samples using the highly parallel quantitative real-time PCR format available as MFCs. To assess the reproducibility of the platform,

we first analyzed intercard variability using a reference card loaded with eight randomly chosen tumor samples from the other MFCs used in this study. This approach confirmed that all PCR reactions have comparable amplification efficiencies and minimal interrun variability, resulting in equal  $C_t$  value recording and constant  $\delta C_t$ 's between plates. We found a high correlation of gene expression, suggesting a high intercard reproducibility of quantitative PCR results, rendering this application capable, in principle, of addressing clinical samples in a reproducible manner. The consistency of results between different batches of MFCs, laboratories, and quantitative PCR machines must still be addressed in multisite studies because it has been pointed out that only stringent quality controls ensure reproducibility of microarray-based results between laboratories (27). It is also striking that, at least for some genes, there were considerable differences in correlation between gene expression in real-time PCR and Affymetrix chip analyses. A recent study pointed out that differences in microarray and real-time PCR results using MFCs may occur if genes are expressed at low levels or if the difference in gene expression between samples is low (28). Platform-dependent differences (hybridization versus amplification) and insufficient specificity of the array probes might also account for lack of correlation between results obtained on the Affymetrix and MFC platforms. Additionally, interrogation of different gene products resulting from alternative splicing must be taken into consideration. The latter might account for differences detected for *TrkA/NTRK1* mRNA expression, displaying a low correlation coefficient between real-time PCR and array analysis. Recent reports indicate the existence of an alternative oncogenic splice variant, TrkAIII, present in aggressive neuroblastomas (29). This may explain why high *TrkA* expression is, in general, a hallmark of benign tumors but was shown to be elevated in some relapsing tumors by MFC quantitative PCR. Therefore, next-generation gene-based outcome prediction should rather be focusing on exon-specific expression rather than gene-specific expression.

Because some genes included on this first-generation MFC proved to be uninformative for prediction of neuroblastoma outcome, the gene list should also be revised. We previously



**Fig. 3.** Kaplan-Meier analyses for patients stratified by real-time PCR – based predictions. PAM analysis was done on 63 neuroblastoma patients by leave-one-out cross-validation predicting either event-free survival or relapse.



**Fig. 4.** A, graphical representation of the receiver operator characteristics of CASPAR-based predictions for the individual risk of relapsing neuroblastoma based on real-time PCR data. Shown here is the AUC as a function of time derived from receiver operating characteristic analyses. If all predictions were correct, the AUC value was 1. The AUC value is  $>0.7$  for  $t > 3$  yrs, which is in line with other advanced outcome prediction studies using microarray data. B, Kaplan-Meier analysis of patients stratified by CASPAR decisions. Patients either predicted to have an early relapse within 3 yrs of diagnosis (*short time to relapse*) are compared with patients with prediction of event-free survival or a late relapse (*no relapse or relapse  $>3$  yrs*). This allows for a significant discrimination between event-free survival and relapse patients ( $P = 0.0006$ , log-rank test).

reported accuracies of 80% and 85% in predicting early recurrence of neuroblastoma using SVM and PAM to analyze Affymetrix array data, respectively (1). Whereas SVM did slightly worse on the real-time PCR data, prediction accuracy obtained on MFC quantitative PCR data using PAM analysis was comparable to that on Affymetrix data. Generally, classification of neuroblastoma patients by high-level analysis according to their disease status as event-free survival or relapse worked with comparable efficiencies of 80% to 85% using either MFC quantitative PCR or Affymetrix array data. Interestingly, the same three patients were misclassified by the predictors generated from analysis of either Affymetrix array or MFC data. This might indicate that rather therapy-related than biology-based reasons account for the outcome of these particular patients. Alternatively, there might be more than one biological

signature for relapsing neuroblastoma, which is not addressed by the gene set investigated in the present study. Because genes from the frequently deleted chromosomal region, 1p36, were also included in our analysis, we attempted to predict the chromosome 1p status (normal 1p or loss of 1p) based on gene expression. This was feasible in principle, as Wang et al. (30) have shown reduced expression of multiple genes on chromosome 1p in cases of neuroblastoma with 1p loss of heterozygosity. Although our MFC was not designed for the purpose of detecting 1p aberrations, prediction accuracy of 1p status (normal versus loss) was 88% by PAM analysis. We could further confirm the strong association between *MYCN* expression and 1p loss described earlier (31). Interestingly, overexpression of proteasome components was highly correlated with 1p loss of heterozygosity as well. Therefore, it is tempting to speculate that patients with 1p loss might especially profit from specific therapies involving proteasomal inhibitors such as Velcade. Finally, loss of 1p was also inversely correlated to *NTRK1* expression. This relationship is intuitively comprehensible but has never been reported before, although the association between *NTRK1* expression and favorable outcome, as well as the anticorrelation with *MYCN* amplification, has previously been documented (31, 32). These results show that expression of neuroblastoma-specific genes also reflects the genomics of neuroblastoma, at least in terms of 1p status.

Interestingly, none of the methods applied here uses *MYCN* expression for decision-making when clinical outcome is addressed. This further corroborates the notion that *MYCN* expression is not necessarily as informative as *MYCN* amplification (33). Additionally, it has been pointed out recently that high-level *MYCN* expression is associated with favorable outcome in neuroblastoma lacking *MYCN* amplification (34). Thus, determining *MYCN* expression levels cannot substitute for *MYCN* status analyses by fluorescence *in situ* hybridization or other methods.

To predict the individual risk of suffering a neuroblastoma relapse, we did PAM- and CASPAR-based analyses on the neuroblastoma MFC data. Kaplan-Meier analysis using the decisions of the respective methods revealed a highly significant discrimination of patient outcome predicted both by PAM (Fig. 3A) and CASPAR (Fig. 4B). Moreover, a powerful discrimination between patients with event-free survival or relapse was possible not only in the cohort but also in a time-dependent manner with AUC values  $>0.7$  for  $t > 5$  years after diagnosis (Fig. 4A and B), emphasizing the accuracy of the combination of real-time PCR and CASPAR analyses. Application of either microarray- or real-time PCR-based methods to clinical decision-making requires easy-to-perform and reliable patient-specific predictions. At present, molecular diagnostics based on gene expression profiling is entering the clinical setting in many prospective studies. However, the advantage of highly parallel real-time PCR methods such as MFCs over conventional microarrays is their efficiency and the ease of implementation in decentralized institutions.

## References

- Schramm A, Schulte JH, Klein-Hitpass L, et al. Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. *Oncogene* 2005;24:7902–12.
- Wei JS, Greer BT, Westermann F, et al. Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. *Cancer Res* 2004;64:6883–91.
- Ohira M, Oba S, Nakamura Y, et al. Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. *Cancer Cell* 2005;7:337–50.

4. Yauk CL, Berndt ML, Williams A, Douglas GR. Comprehensive comparison of six microarray technologies. *Nucleic Acids Res* 2004;32:e124.
5. Wang Y, Barbacioru C, Hyland F, et al. Samaha RR. Large scale real-time PCR validation on gene expression measurements from two commercial long-oligonucleotide microarrays. *BMC Genomics* 2006;7:59.
6. Larkin JE, Frank BC, Gavras H, Sultana R, Quackenbush J. Independence and reproducibility across microarray platforms. *Nat Methods* 2005;2:337–44.
7. Gordon GJ, Jensen RV, Hsiao LL, et al. Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. *Cancer Res* 2002;62:4963–7.
8. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. *N Engl J Med* 2004;350:1828–37.
9. Segal MR. Microarray gene expression data with linked survival phenotypes: diffuse large-B-cell lymphoma revisited. *Biostatistics* 2006;7:268–85.
10. Winnepeninckx V, Lazar V, Michiels S, et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. *J Natl Cancer Inst* 2006;98:472–82.
11. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. *Genome Biol* 2002;3:RESEARCH0034.
12. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. *Proc Natl Acad Sci U S A* 2001;98:5116–21.
13. Chang CC, Lin CJ. LIBSVM: a library for support vector machines. *Neural Comput* 2001;13:2119–47.
14. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. *Proc Natl Acad Sci U S A* 2002;99:6567–72.
15. Kaderali L, Zander T, Faigle U, Wolf J, Schultze JL, Schrader R. CASPAR: a hierarchical bayesian approach to predict survival times in cancer from gene expression data. *Bioinformatics* 2006;22:1495–502.
16. Li L. Survival prediction of diffuse large-B-cell lymphoma based on both clinical and gene expression information. *Bioinformatics* 2006;22:466–71.
17. Li L, Li H. Dimension reduction methods for microarrays with application to censored survival data. *Bioinformatics* 2004;20:3406–12.
18. Guo L, Ma Y, Ward R, Castranova V, Shi X, Qian Y. Constructing molecular classifiers for the accurate prognosis of lung adenocarcinoma. *Clin Cancer Res* 2006;12:3344–54.
19. Carter SL, Eklund AC, Mecham BH, Kohane IS, Szallasi Z. Redefinition of Affymetrix probe sets by sequence overlap with cDNA microarray probes reduces cross-platform inconsistencies in cancer-associated gene expression measurements. *BMC Bioinformatics* 2005;6:107.
20. Schlingemann J, Habtemichael N, Itrich C, et al. Patient-based cross-platform comparison of oligonucleotide microarray expression profiles. *Lab Invest* 2005;85:1024–39.
21. Gwinn MR, Keshava C, Olivero OA, Humsi JA, Poirier MC, Weston A. Transcriptional signatures of normal human mammary epithelial cells in response to benzo[*a*]pyrene exposure: a comparison of three microarray platforms. *OMICS* 2005;9:334–50.
22. Cheung IY, Lo Piccolo MS, Kushner BH, Kramer K, Cheung NK. Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma. *J Clin Oncol* 2003;21:1087–93.
23. Henrich KO, Fischer M, Mertens D, et al. Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients. *Clin Cancer Res* 2006;12:131–8.
24. Lambooy LH, Gidding CE, van den Heuvel LP, et al. Real-time analysis of tyrosine hydroxylase gene expression: a sensitive and semiquantitative marker for minimal residual disease detection of neuroblastoma. *Clin Cancer Res* 2003;9:812–9.
25. Swerts K, De Moerloose B, Dhooge C, et al. Potential application of ELAVL4 real-time quantitative reverse transcription-PCR for detection of disseminated neuroblastoma cells. *Clin Chem* 2006;52:438–45.
26. Roberts SS, Mori M, Pattee P, et al. GABAergic system gene expression predicts clinical outcome in patients with neuroblastoma. *J Clin Oncol* 2004;22:4127–34.
27. Irizarry RA, Warren D, Spencer F, et al. Multiple-laboratory comparison of microarray platforms. *Nat Methods* 2005;2:345350.
28. Abruzzo LV, Lee KY, Fuller A, et al. Validation of oligonucleotide microarray data using microfluidic low-density arrays: a new statistical method to normalize real-time RT-PCR data. *Biotechniques* 2005;38:785–92.
29. Tacconelli A, Farina AR, Cappabianca L, et al. TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma. *Cancer Cell* 2004;6:347–60.
30. Wang Q, Diskin S, Rappaport E, et al. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. *Cancer Res* 2006;66:6050–62.
31. Nakagawara A, Arima M, Azar C, Scavarda N, Brodeur G. Inversion relationship between Trk expression and N-myc-amplification in human neuroblastomas. *Cancer Res* 1992;52:1364–8.
32. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM. Association between high levels of expression of the Trk gene and favorable outcome in human neuroblastomas. *N Engl J Med* 1993;328:847–54.
33. Cohn SL, London WB, Huang D, et al. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. *J Clin Oncol* 2000;18:3604–13.
34. Tang XX, Zhao H, Kung B, et al. The MYCN enigma: significance of MYCN expression in neuroblastoma. *Cancer Res* 2006;66:2826–33.